Home
World Journal of Biology Pharmacy and Health Sciences
ISSN Approved | International, Peer reviewed, Referred, Open access Journal

Main navigation

  • Home
    • Journal Information
    • Abstracting and Indexing
    • Editorial Board Members
    • Reviewer Panel
    • Journal Policies
    • WJBPHS CrossMark Policy
    • Publication Ethics
    • Current Issue
    • Issue in Progress
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Become a Reviewer panel member
    • Join as Editorial Board Member
  • Contact us
  • Downloads

ISSN Approved Journal | | IMPACT FACTOR 8.16 | | eISSN: 2582-5542 | |  Free Crossref DOI 

Fast Publication within 2 days | | Low Article Processing Charges | | Peer Reviewed and Referred Journal

Research and review articles are invited for publication in September 2026 (Volume 27, Issue 3) Submit Paper

Market review on Clopidogrel Tablet

Breadcrumb

  • Home
  • Market review on Clopidogrel Tablet

Prachi Rahul Kabra, Trupti Vijay Beldar * and Shweta Ganesh Bodke

Ideal College of Pharmacy, Kalyan, Maharashtra, India.

Review Article
 
World Journal of Biology Pharmacy and Health Sciences, 2024, 19(03), 347–356
Article DOI: 10.30574/wjbphs.2024.19.3.0640
DOI url: https://doi.org/10.30574/wjbphs.2024.19.3.0640

Received on 03 August 2024; revised on 11 September 2024; accepted on 14 September 2024

Antiplatelet drugs are drugs which interfere with platelet function and are useful in the prophylaxis of thromboembolic disorders. Clopidogrel is the most commonly used Antiplatelet drug(1). Clopidogrel was first reported in 1987 to be an inhibitor of ADP induced platelet activation. It was first approved by US-FDA in1997 and was developed and manufactured by bristol-myers squibb (BMS) in collaboration with Sanofi-Aventis. Plavix is a patented brand of Clopidogrel and plavix's patent expired in May, 2012. Plavix (clopidogrel) has been the most prescribed antiplatelet brand-name drug for the prevention of heart attack or stroke, and was the second best-selling drug in the world, with $9.4 billion in global sales in 2010(3). After listening to a lot of people's opinion about clopidogrel, it has been noticed that this drug works very well in about 70to 80% of the people. Some people also experience side effect mainly bleeding, headache, stomach and abdominal pain.re
The growing global population of people suffering from cardiovascular illnesses and other disorders is the fundamental reason for the increased demand for clopidogrel. Furthermore, in the next six years, rising economies in the Asia Pacific area are predicted to be the largest consumers of clopidogrel due to changing lifestyles and an increase in the number of patients with cardiovascular illnesses (3). Furthermore, the patentexpiration of the clopidogrel medicine is expected to open the floodgates for various pharmaceutical businesses to enter the clopidogrel drug production business.Recent studies have raised concern that a significantclinical interaction may exist between Clopidogrel and proton pump inhibitors. Studies suggest PPI may diminish Clopidogrels effect (1).
Since the patent expired in 2012 the drug is now available in over 100 different brands and has many generic formulations. According to many pharma experts the demand for this drug is expected to increase in the future due to the increasing incidence of cardiovascular diseases.
After all the drug cropidogrel has become a necessity for many people today considering the deadly disease of stroke and heart attack (2).

Clopidogrel; Patent expiration; Side effects; Necessity

https://wjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2024-0640.pdf

Preview Article PDF

Prachi Rahul Kabra, Trupti Vijay Beldar and Shweta Ganesh Bodke. Market review on Clopidogrel Tablet. World Journal of Biology Pharmacy and Health Sciences, 2024, 19(03), 347–356. Article DOI: https://doi.org/10.30574/wjbphs.2024.19.3.0640

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content


Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


Copyright © 2026 World Journal of Biology Pharmacy and Health Sciences (WJBPHS) - All rights reserved

Developed & Designed by VS Infosolution